Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
SRRK
Strong SellHot AirScholar Rock Holding Corporation · Healthcare · United States · $7.0B · Avg Vol: $60M/d
COMPANY DESCRIPTION
Scholar Rock Holding Corporation is a clinical-stage biopharmaceutical company focused on discovering and developing novel medicines for serious diseases by targeting the transforming growth factor beta (TGFβ) superfamily. Its proprietary platform and precision approach to modulating protein activation offer a unique competitive advantage in addressing unmet medical needs. The company's innovative drug candidates aim to treat neuromuscular and fibrotic diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 33.2M | 0 | 0 | 0 | — | — | 5.7M | 146.1M | 34.5% |
| EPS | -0.97 | -1.99 | -2.47 | -3.29 | — | -3.31 | -3.12 | -2.57 | — |
| Shares | 119.8M | 76.0M | 93.8M | 108.5M | -9.5% | 121.8M | — | — | — |
| Debt | 69.4M | 61.8M | 65.1M | 108.9M | 16.2% | 203.8M | — | — | — |
| Equity | 260.2M | 225.2M | 368.6M | 245.5M | -1.9% | — | — | — | — |
| Op CF | -132.7M | -145.2M | -200.9M | -300.0M | — | -296.8M | — | — | — |
| Inv CF | -171.7M | 41.1M | -76.1M | 218.7M | — | — | — | — | — |
| Fin CF | 194.8M | 102.6M | 353.0M | 228.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SRRK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SRRK | Scholar Rock Holding Corporation(you) | $7.0B | 19 | Strong Sell |
| CGON | CG Oncology, Inc. | $6.6B | 17 | Strong Sell |
| IMVT | Immunovant, Inc. | $8.5B | 21 | Sell |
| ERAS | Erasca, Inc. | $6.3B | 14 | Strong Sell |
| SYRE | Spyre Therapeutics, Inc. | $8.0B | 23 | Sell |
| IBRX | ImmunityBio, Inc. | $8.5B | 22 | Sell |
| DNTH | Dianthus Therapeutics, Inc. | $5.9B | 23 | Sell |
| DFTX | Definium Therapeutics, Inc. | $5.5B | 22 | Sell |
| KYMR | Kymera Therapeutics, Inc. | $9.7B | 21 | Sell |
| COGT | Cogent Biosciences, Inc. | $6.0B | 12 | Strong Sell |
Peer medians: ROE -30.5% · P/E 27.0x · Gross margin 58.3%